Cidara Therapeutics: Major Partnerships & Phase 3 Studies Underway
Oct. 13, 2021
Cidara (Nasdaq: CDTX) is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform. US rezafungin potential sales opportunity estimated at $750 million if approved for both treatment and prophylaxis indications. Visit CDTXinfo.com to learn more.
